From the Departments of Neurology (L.C.J., E.G.P.D., T.d.H., J.C.v.S., J.M.P.), Epidemiology (T.d.H.), Psychiatry, Unit of Medical Psychology and Psychotherapy (R.T.), and Clinical Genetics (R.v.M.), Erasmus Medical Center, Rotterdam; Department of Radiology (L.C.J., E.G.P.D.), Leiden University Medical Center, Leiden; Departments of Neurology (E.G.P.D.) and Clinical Genetics (J.C.v.S.), VU Medical Center, Amsterdam; and Department of Neurology (T.d.H.), Sint Franciscus Gasthuis, Rotterdam, the Netherlands.
Neurology. 2016 Jul 26;87(4):384-91. doi: 10.1212/WNL.0000000000002895. Epub 2016 Jun 29.
In this prospective cohort study, we performed a 2-year follow-up study with neuropsychological assessment in the presymptomatic phase of familial frontotemporal dementia (FTD) due to GRN and MAPT mutations to explore the prognostic value of neuropsychological assessment in the earliest FTD disease stages.
Healthy, at-risk, first-degree relatives of patients with FTD who had a MAPT (n = 13) or GRN mutation (n = 30) and healthy controls (n = 39) underwent neuropsychological assessment at baseline and 2-year follow-up. We investigated baseline and longitudinal differences, as well as relationship with age and estimated years before symptom onset.
At baseline, GRN mutation carriers showed lower scores on mental processing speed than healthy controls (p = 0.043). Two years later, MAPT mutation carriers showed a steeper decline than GRN mutation carriers on social cognition (p = 0.002). Older age was related to cognitive decline in visuoconstruction (p = 0.005) and social cognition (p = 0.026) in MAPT. Memory significantly declined from 8 to 6 years before estimated symptom onset in MAPT and GRN mutation carriers, respectively, and language and social cognition declined only in MAPT mutation carriers from 7 to 5 years before estimated symptom onset, respectively (p < 0.05).
Using longitudinal neuropsychological assessment, we detected gene-specific neuropsychological patterns of decline in, e.g., social cognition, memory, and visuoconstruction. Our results confirm the prognostic value of neuropsychological assessment as a potential clinical biomarker in the presymptomatic phase of familial FTD.
在这项前瞻性队列研究中,我们对携带 GRN 和 MAPT 突变的家族性额颞叶痴呆(FTD)的前驱期患者进行了为期 2 年的神经心理学评估随访研究,以探索神经心理学评估在最早的 FTD 疾病阶段的预后价值。
健康、有风险的、携带 FTD 患者 MAPT(n = 13)或 GRN 突变(n = 30)的一级亲属以及健康对照者(n = 39)在基线和 2 年随访时接受神经心理学评估。我们研究了基线和纵向差异,以及与年龄和估计发病前年限的关系。
在基线时,GRN 突变携带者的心理加工速度得分低于健康对照者(p = 0.043)。两年后,MAPT 突变携带者的社会认知能力下降速度快于 GRN 突变携带者(p = 0.002)。年龄较大与 MAPT 中的视空间构建认知(p = 0.005)和社会认知(p = 0.026)的认知下降有关。在 MAPT 和 GRN 突变携带者中,分别从预计发病前 8 年和 6 年前记忆开始显著下降,分别从预计发病前 7 年和 5 年前语言和社会认知开始下降,仅在 MAPT 突变携带者中(p < 0.05)。
使用纵向神经心理学评估,我们检测到了例如社会认知、记忆和视空间构建等方面的基因特异性神经心理衰退模式。我们的研究结果证实了神经心理学评估在家族性 FTD 前驱期作为潜在临床生物标志物的预后价值。